MedTrace Logo

The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia

NCT02407548 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-06-22

No results posted yet for this study

Summary

In previous study the investigators found that CoQ10 can improve cholesterol efflux from macrophages in cell model, ApoE mice model and small-scale of healthy volunteers. In addition, CoQ10 has strong antioxidant activity and is an essential factor of mitochondria electron transport chain. So the investigators hypothesize that CoQ10 may have some health promotion effect on dyslipidemia, risk factor of atherosclerosis and other cardiovascular diseases. On this purpose, the investigators are going to recruit 150 dyslipidemia patients to supply CoQ10+vitamin E or CoQ10 alone or placebo in different doses for 24 weeks to explore the effects of CoQ10 on cholesterol efflux and lipid profiles on dyslipidemia.

Conditions

Interventions

DIETARY_SUPPLEMENT

coenzyme Q10 vitamin E softgel

4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.

DIETARY_SUPPLEMENT

coenzyme Q10 softgel

4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.

DIETARY_SUPPLEMENT

placebo softgel

4 placebo softgels per day. Keep normal lift style unchanged.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • ling wenhua, professor · SUN YAY-SEN UNIVERSITY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02407548 on ClinicalTrials.gov